← ANALYST RATINGS · TIPRANKS
Novartis (NVS): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy3 Hold0 Sell
Ratings of 5 analysts in the last 3 months · top analysts only12-month forecast
Based on 5 price targets given in the last 3 months, the average target is $158, the highest $180, the lowest $136. The average is +4.8% from the last price of $151.
Analyst ratings 10
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Sachin Jain★★★★★★★★★★#5208 · hits 53% · avg +2.2% | Bank of America Securities | $185 | Buy | +22.8% | Reiterated | 12.10.26on TipRanks 07:30 | +0.1%next day −1.0% | ↗ |
| Thibault Boutherin★★★★★★★★★★#3632 · hits 62% · avg +7.0% | Morgan Stanley | $170 → $156−8.2% | Buy | +3.6% | Reiterated | 06.10.26on TipRanks 11:55 | −0.6%next day +2.0% · 5 days +1.3% | ↗ |
| Rajesh Kumar★★★★★★★★★★#1587 · hits 62% · avg +14.5% | HSBC | $123 → $136+10.6% | Hold | −9.7% | Upgrade | 10.09.26on TipRanks 05:00 | +0.6%next day −1.1% · 5 days +1.9% | ↗ |
| AI xAi Drug Manufacturers - GeneralxAI Grok-3 | TipRanks - xAI | $177 → $150−15.3% | Hold | −0.4% | Downgrade | 09.09.26on TipRanks 09:06 | — | |
| AI DeepSeek Drug Manufacturers - GeneralDeepSeek R1-0528 | TipRanks - DeepSeek | $171 → $151−11.7% | Hold | +0.3% | Downgrade | 09.09.26on TipRanks 09:06 | — | |
| AI OpenAI Drug Manufacturers - GeneralOpenAI 4o | TipRanks - OpenAI | $167 → $149−10.8% | Hold | −1.1% | Reiterated | 09.09.26on TipRanks 09:06 | — | |
| AI Anthropic Drug Manufacturers - GeneralAnthropic Opus-4.1 | TipRanks - Anthropic | $161 → $145−9.9% | Hold | −3.7% | Reiterated | 09.09.26on TipRanks 09:06 | — | |
| AI Google Drug Manufacturers - GeneralGemini 2.5Pro | TipRanks - Google | $172 → $152−11.6% | Buy | +0.9% | Reiterated | 09.09.26on TipRanks 09:06 | — | |
| AI PerPlexity Drug Manufacturers - GeneralPerPlexity SonarPro | TipRanks - PerPlexity | $177 → $156−11.9% | Buy | +3.6% | Reiterated | 09.09.26on TipRanks 09:06 | — | |
| Steve Scala★★★★★★★★★★#1275 · hits 63% · avg +10.5% | TD Cowen | $180 | Hold | +19.5% | Reiterated | 08.09.26on TipRanks Sep 9 05:45 | −13.4%next day +0.3% · 5 days +1.8% | ↗ |
| Kerry Holford★★★★★★★★★★#2798 · hits 58% · avg +8.7% | Berenberg Bank | $141 → $147+4.3% | Hold | −2.4% | Reiterated | 27.07.26on TipRanks Jul 28 01:35 | +0.7%next day +2.2% · 5 days −4.1% | ↗ |
| Jasper Hellweg★★★★★★★★★★#2291 · hits 57% · avg +7.4% | Argus Research | $170 | Buy | +12.9% | Reiterated | 24.07.26on TipRanks Jul 29 06:19 | −0.8%next day +0.7% · 5 days −0.4% | ↗ |
| Unknown Analyst | Goldman Sachs | $140 → $139−0.7% | Sell | −7.7% | Reiterated | 22.07.26on TipRanks Jul 23 21:14 | −0.4%next day +3.2% · 5 days +6.2% | ↗ |
| Justin Smith★★★★★★★★★★#2325 · hits 60% · avg +9.0% | Bernstein | — | Hold | — | Initiated | 19.03.26on TipRanks 16:35 | 0.0%next day +0.4% · 5 days +3.7% | ↗ |
| Emily Field★★★★★★★★★★#5009 · hits 45% · avg +1.9% | Barclays | — | Hold | — | Upgrade | 06.01.26on TipRanks 12:00 | +2.6%next day +0.1% · 5 days −0.7% | ↗ |
| Richard Vosser★★★★★★★★★★#4454 · hits 49% · avg +2.0% | J.P. Morgan | — | Hold | — | Reiterated | 20.11.25on TipRanks Nov 21 10:40 | −0.8%next day +1.4% · 5 days +0.1% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Novartis
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 05.10.26: target $154 at a price of $141 (+9.5%); now: $159 at $151 (+5.6%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 2 | 1 | 2 | 2 | 1 | 1 |
| Hold | 3 | 2 | 4 | 3 | 4 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 27.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $2.26 (from $2.16 to $2.33). Last quarter: $2.41.
Sales
Next quarter’s sales estimate — $14.6B (from $14.3B to $15.1B). Last quarter: $14.4B.
Best top-analyst consensus in the sector · Healthcare
About Novartis
- CEO: Vasant Narasimhan
- Employees: 75,267
- Lichtstrasse 35, Basel, BS, 4056, CH
- www.novartis.com
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Data from the stock’s TipRanks forecast page, read 120 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗